Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.75
-0.7%		$30.53
$22.64
▼
$50.79
$740.65M0.72808,307 shs661,300 shs
GLAS
Glass House Brands
$7.89
-1.1%		$9.89
$5.15
▼
$13.93
$743.83MN/A493,246 shs859,680 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.15
-0.2%		$4.44
$1.93
▼
$12.46
$198.15M-0.08235,082 shs135,947 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.36
-0.1%		$9.85
$8.07
▼
$18.31
$676.33M0.51944,822 shs1.39 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%-3.31%-19.18%-34.32%-39.67%
GLAS
Glass House Brands
0.00%-11.24%-20.78%+789,099,900.00%+789,099,900.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-6.32%+5.87%-7.98%+90.80%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
0.00%-12.00%-8.93%-19.38%-32.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.75
-0.7%		$30.53
$22.64
▼
$50.79
$740.65M0.72808,307 shs661,300 shs
GLAS
Glass House Brands
$7.89
-1.1%		$9.89
$5.15
▼
$13.93
$743.83MN/A493,246 shs859,680 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.15
-0.2%		$4.44
$1.93
▼
$12.46
$198.15M-0.08235,082 shs135,947 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.36
-0.1%		$9.85
$8.07
▼
$18.31
$676.33M0.51944,822 shs1.39 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%-3.31%-19.18%-34.32%-39.67%
GLAS
Glass House Brands
0.00%-11.24%-20.78%+789,099,900.00%+789,099,900.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-6.32%+5.87%-7.98%+90.80%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
0.00%-12.00%-8.93%-19.38%-32.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.50
Moderate Buy$48.50113.19% Upside
GLAS
Glass House Brands
2.00
Hold$16.00102.76% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.75
Reduce$10.33149.00% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.78
Moderate Buy$21.25154.19% Upside

Current Analyst Ratings Breakdown

Latest NERV, GLAS, PHAT, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
GLAS
Glass House Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$45.00
9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$10.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$45.00
9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$10.00
9/4/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
8/20/2026
GLAS
Glass House Brands
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/19/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$56.00 ➝ $48.00
8/14/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$18.00 ➝ $14.00
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$780.57M0.95$15.27 per share1.49$9.54 per share2.38
GLAS
Glass House Brands
N/AN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$175.11M3.86N/AN/A($6.14) per share-1.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$62.87M$1.2418.355.10N/A5.93%91.43%15.57%11/5/2026 (Estimated)
GLAS
Glass House Brands
N/AN/AN/A39.46N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.87N/AN/AN/AN/AN/A-31.72%11/4/2026 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$221.25M-$1.28N/A7.21N/A-41.34%N/A-20.81%10/29/2026 (Estimated)

Latest NERV, GLAS, PHAT, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
8/6/2026Q2 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.72$1.92+$0.20-$0.46$199.63 million$199.88 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
GLAS
Glass House Brands
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.32
1.03
0.84
GLAS
Glass House Brands
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
20.15
20.14
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
1.92
1.87

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
GLAS
Glass House Brands
N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%

Insider Ownership

CompanyInsider Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1.85%
GLAS
Glass House Brands
N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
9.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.56 million31.95 millionOptionable
GLAS
Glass House Brands
N/A93.80 millionN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
947.75 million46.94 millionNot Optionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11080.90 million73.35 millionOptionable

Recent News About These Companies

Phathom Pharmaceuticals (NASDAQ:PHAT) Research Coverage Started at Leerink Partners
September 12 at 2:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31018284
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year Low - What's Next?
September 11 at 12:22 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-phathom-pharmaceuticals-nasdaq-phat-sets-new-1-year-low-whats-next-2026-09-11/
Opaleye Management Inc. Purchases New Shares in Phathom Pharmaceuticals, Inc. $PHAT
September 11 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-purchases-new-shares-in-phathom-pharmaceuticals-inc-phat-2026-09-11/
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Moderate Buy" by Brokerages
September 11 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-phathom-pharmaceuticals-inc-nasdaq-phat-given-average-rating-of-moderate-buy-by-brokerages-2026-09-11/
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Leerink Partners
September 10 at 7:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-phathom-pharmaceuticals-nasdaq-phat-stock-rating-upgraded-by-leerink-partners-2026-09-10/
Hsbc Holdings PLC Invests $7.70 Million in Phathom Pharmaceuticals, Inc. $PHAT
September 10 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-invests-770-million-in-phathom-pharmaceuticals-inc-phat-2026-09-10/
Leerink Partners initiates coverage of Phathom Pharmaceuticals with market perform
September 10 at 1:39 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/leerink-partners-initiates-coverage-of-phathom-pharmaceuticals-with-market-perform/ar-AA2bUHD6
PHAT stock falls 7% as Leerink sees little near-term upside — CEO plays down upcoming rival
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/phat-stock-falls-7-as-leerink-sees-little-near-term-upside-ceo-plays-down-upcoming-rival/ar-AA2bTIk9
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944441-phathom-pharmaceuticals-specialist-economics-strengthen-the-bull-case
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.3% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-phathom-pharmaceuticals-nasdaq-phat-trading-down-53-should-you-sell-2026-09-09/
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT
September 9, 2026  |  marketscreener.comM
Bank of New York Mellon Corp Purchases Shares of 152,313 Phathom Pharmaceuticals, Inc. $PHAT
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-shares-of-152313-phathom-pharmaceuticals-inc-phat-2026-09-09/
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354051/0/en/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc.
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4525129-shares-in-phathom-pharmaceuticals-inc-phat-acquired-by-blackrock-inc-2026-09-01/
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-709695-phathom-pharmaceuticals-inc-phat-2026-08-29/
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2% - What's Next?
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/phathom-pharmaceuticals-nasdaqphat-shares-down-82-whats-next-2026-08-20/
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc.
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3496808-shares-in-phathom-pharmaceuticals-inc-phat-acquired-by-carlyle-group-inc-2026-08-18/
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/phathom-pharmaceuticals-inc-nasdaqphat-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-17/
Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth
August 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-earnings-call-signals-profitable-growth?utm_source=marketbeat.com&utm_medium=referral
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338515/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-phathom-pharmaceuticals-inc-phat.html
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
August 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260803710047/en/phat-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-phathom-pharmaceuticals-inc.-phat/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Copper pipes and sheet stacks in a warehouse open to electrical transmission towers and a power substation at sunset.
Copper Surges as Shifting Trade Policy and AI Demand Collide
By Chris Markoch | September 2, 2026
Metallic Apple logo mounted on a pillar inside an Apple Store, with the storefront glass entrance visible in the background.
Why Are Analysts Freaking Out About Apple's All-Glass iPhone?
By Sam Quirke | August 14, 2026
Laptop displaying a stock price chart on a desk, with background TVs showing financial news and a city skyline.
3 Stocks With September Catalysts Investors Shouldn’t Ignore
By Ryan Hasson | September 6, 2026
Exterior of a Best Buy retail store showing the illuminated logo above glass entrance doors and parked cars.
Is Best Buy the AI Winner Hiding in the Electronics Aisle?
By Sam Quirke | August 15, 2026
Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$22.75 -0.17 (-0.74%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$22.76 +0.01 (+0.04%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Glass House Brands NYSE:GLAS

$7.89 -0.09 (-1.12%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$7.94 +0.04 (+0.56%)
As of 09/11/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$4.15 -0.01 (-0.24%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.16 +0.00 (+0.12%)
As of 09/11/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.36 -0.01 (-0.12%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$8.28 -0.07 (-0.90%)
As of 09/11/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas